Epic Sciences Stock

epicsciences.comHealthcare / BioTech & PharmaFounded: 2008Funding to Date: $63.38MM

Epic Sciences, founded in 2008, is a diagnostics company seeking to to improve cancer management. The company aims to provide easily accessible and real-time biopsy material to guide personalized medicine for numerous pharmaceutical companies and major cancer centers. The Epic Sciences platform is designed with the goal of identifying and characterizing rare cells including circulating tumor cells ("CTCs"). Epic Sciences is headquartered in San Diego, California.

Register To Buy and Sell Shares

For more details on financing and valuation for Epic Sciences, register or login.

Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Log in

OverviewFinancingsValuation

Enterprise Value

Powered by Forge Data

Access Epic Sciences’ valuation and stock price.

View secondary pricing information, VWAP and distribution waterfall. And seek potentially outsized returns with same day private market data for private companies like Epic Sciences.

Become part of the Secondary Marketplace, catering to both individual and institutional investors.

Register

Animation displayed is not current and securities are shown for illustrative purposes only.

Epic Sciences investors also invested in these private companies

Domain Associates
Pagoda Investment
U.S. Department of Health and Human Services
Arcus Ventures
Labcorp Ventures
Altos Capital Partners
Genomic Health
Hermed Capital
VI Ventures

Team

Management Team

Pascal Bamford Ph.D
Chief Scientific Officer and Head of Laboratory Operations
Dena Marrinucci Ph.D
Co-Founder & Member Clinical Advisory Board
Murali Prahalad Ph.D
Chief Executive Officer & President
Ryan Dittamore
Chief of Medical Innovation and Head of Translational Research Partnerships
Ian Miller JD
Chief Business Officer and General Counsel
Dave Henderson
Chief Information Officer

Board Members

Evgeny Zaytsev Ph.D
RusnanoMedInvest
Kim Kamdar Ph.D
Domain Associates
Andrew ElBardissi MD
Deerfield Management
Simon Greenwood Ph.D
Roche Venture Fund

Frequently Asked Questions About Epic Sciences’ Stock

plusminus
Can you buy Epic Sciences’ stock?
Epic Sciences is not publicly traded on NYSE or NASDAQ in the U.S. To buy Epic Sciences’ stock you need to be an accredited investor. Learn more about how to invest in the private market or register today to get started.
plusminus
Can you sell Epic Sciences’ stock?
Yes, you can sell stock of a private company like Epic Sciences. Forge can help you sell your Epic Sciences stock in a way that works for you and the company. So if you are seeking liquidity, register with us today to get started.
plusminus
What is Epic Sciences’ stock price?
Epic Sciences is a privately held company and therefore does not have a public stock price. However, you may access Epic Sciences’ private market stock price with Forge Data.
plusminus
What is Epic Sciences’ stock ticker symbol?
Epic Sciences does not have an official ticker symbol because this company is not currently publicly traded.
plusminus
Can institutional investors buy and sell private market stocks?
Yes. As one of the largest trading platform for the private market, Forge helps institutional investors seek liquidity as they buy and sell private stock for their portfolios or their clients. Our private market specialists have decades of experience working with institutional firms. Learn more or register today to get started.

News Highlights

Epic Sciences Raises $24M in Series G Financing to Continue Funding Commercialization of DefineMBC
Epic Sciences, Inc. (“Epic” or “Epic Sciences”), a privately held diagnostics company, has completed a $24 million Series G which together with its $43 million Series F financing, totals $67 million raised in the last twelve months.
Epic Sciences Closes $52M in Series E Financing | FinSMEs
Epic Sciences, a San Diego, CA-based developer of blood tests that predict therapeutic benefit for cancer patients, completed a $52m Series E financing
Updated on: Jun 16, 2024

PLEASE READ THESE IMPORTANT LEGAL NOTICES & DISCLOSURES

Public news articles listed on this page have been curated by Forge based on several factors including, but not limited to, product updates, changes in organization structure, funding rounds, third-party valuations, and key personnel changes. Changes to this list of articles can be made at any time without notice and should not be relied upon for investment purposes. Forge does not verify the accuracy of the information contained in public news articles.